

Carbon Reduction Plan

Supplier name: Haemonetics Limited, a subsidiary of Haemonetics Corporation

Publication date: January 7, 2026¹

Commitment to achieving Net Zero

Haemonetics Limited has adopted a plan to achieve Net Zero emissions for Haemonetics' UK geographic operations by 2050. Currently, Haemonetics' UK operations include one office and a small fleet of sales vehicles.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured. Fiscal years are referred to throughout this plan as "FY".

Since 2022, we have calculated our global Scope 1 and 2 greenhouse gas ("GHG") emissions on an annual basis using emission quantification methodologies drawn from the Greenhouse Gas Protocol developed by the World Resources Institute and World Business Council for Sustainable Development ("GHG Protocol"). We have set FY2018 as our baseline year for purposes of tracking our progress in reducing total Scope 1 and 2 GHG emissions and evaluating opportunities for further improvements. In FY2025, we recalculated our FY2018 baseline and subsequent fiscal year inventories consistent with the GHG Protocol in order to reflect the sale of the Whole Blood product line within our Blood Center business unit in January 2025. Adjustments to the FY2018 baseline and subsequent historical fiscal year inventories also reflect the impacts of manufacturing facilities and offices we assumed in connection with our acquisitions of OpSens Inc. (Canada) in December 2023 and Advanced Cooling Therapy, Inc. (d/b/a Attune Medical) in April 2024.

Baseline Year: FY2018 (began on April 2, 2017 and ended on March 31, 2018)	
Additional Details relating to the Baseline Emissions calculations: See "Baseline Emissions Footprint" above regarding the FY2025 recalculation of our FY2018 baseline for Scope 1 and Scope 2 emissions. Historical Scope 3 emissions have not been calculated. The choice of a FY2018 baseline is aligned with Haemonetics Corporation's global reporting in the company's 2022 Corporate Responsibility Report, which is available on its website at www.haemonetics.com . We expect to publish our next Corporate Responsibility Report in the first quarter of calendar 2026.	
Baseline year emissions: In FY2018, Haemonetics' UK geographic operations consisted of two small R&D/manufacturing facilities and a small fleet of sales vehicles.	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	71 tCO ₂ e
Scope 2 (market-based)	407 tCO ₂ e
Scope 3 (Included Sources)	Not available. Historical Scope 3 emissions have not been calculated, however a FY22 or FY23 baseline will be established for this category. See note in Current Emissions Reporting.
Total Emissions	478 tCO ₂ e

¹ The Carbon Reduction Plan for Haemonetics Limited was originally published on July 28, 2023 and is updated annually. Our last Carbon Reduction Plan covering our FY2023 emissions was published on December 9, 2024. This update to reflect our recalculated FY2018 baseline and FY2024 and FY2025 emissions data was furnished as of the publication date above.

Current Emissions Reporting

Reporting Years: FY2024 (began on April 2, 2023 and ended on March 30, 2024); FY2025 (began on March 31, 2024 and ended on March 29, 2025)		
In FY2024 and FY2025, Haemonetics' UK geographic operations consisted of one small office building and a small fleet of sales vehicles.		
EMISSIONS	FY2024 TOTAL (tCO ₂ e)	FY2025 TOTAL (tCO ₂ e)
Scope 1	50 tCO ₂ e	31 tCO ₂ e
Scope 2 (market-based)	29 tCO ₂ e	13 tCO ₂ e
Scope 3 (Included Sources)	Haemonetics is currently working with a third party to calculate a global scope 3 emissions inventory. Scope 3 emissions within the UK geographic boundary will be calculated and reported for the following categories: Upstream Transportation & Distribution, Waste Generated in Operations, Business Travel, and Employee Commuting. Scope 3 emissions from Downstream Transportation & Distribution are likely de minimis. This Carbon Reduction Plan will be updated when Scope 3 emissions reporting is available.	
Total Emissions	79 tCO ₂ e	44 tCO ₂ e

Emissions Reduction Targets

Haemonetics' UK scope 1 and 2 GHG emissions have decreased by approximately 91% between our FY2018 baseline year and FY2025. In the long term, Haemonetics Limited is committed to achieving Net Zero for Haemonetics' UK operations by 2050, a reduction of 100% from the applicable 2018 baseline.

Carbon Reduction Projects

Completed Carbon Reduction Initiatives

Between FY2018 and FY2025, Haemonetics' UK scope 1 and 2 GHG emissions decreased by approximately 91%. This is largely due to a transition of business operations from manufacturing to sales within the UK and the effect of various other restructuring-type activities designed to capture efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions. Haemonetics UK's FY2025 total Scope 1 and 2 emissions decreased as compared to FY2024 by approximately 35 tCO₂e driven primarily by reduced vehicle fleet travel and fuel consumption and the transition of a majority of our fleet to hybrid vehicles.

Future Carbon Reduction Initiatives

Scope 1 and Scope 2 Emissions

To continue our progress to achieving Net Zero, in December 2024 we purchased Renewable Energy Guarantees of Origin (REGOs) and nuclear declarations covering 100% of the company's forecasted UK office electricity consumption for calendar years 2025 and 2026. In line with the GHG Protocol, the Company applies the market-based method for reporting Scope 2 emissions where contractual instruments such as REGOs are available. In the future we hope to implement further measures, including:

- Procuring additional renewable electricity as needed

- Implementing energy efficiency projects (lighting, HVAC, insulation, etc.)
- Taking steps to transition the sales vehicle fleet to electric vehicles and examining opportunities to reduce year-over-year increases in fleet operations

Scope 3 Emissions

In the future we hope to implement further measures to reduce our Scope 3 emissions, including:

- Engaging with transportation suppliers to set emissions reduction targets
- Reducing municipal waste by recycling and other diversion measures
- Reducing business travel mileage and utilizing less intense means of transport
- Encouraging lower impact means of commuting, such as biking, public transport, or working virtually

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the Greenhouse Gas Reporting Protocol corporate standard² and uses the appropriate Government emission conversion factors for greenhouse gas company reporting³.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard⁴.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

/s/ James D'Arecca

James D'Arecca, Member of Board of Directors of Haemonetics Limited

Date: January 7, 2026

² <https://ghgprotocol.org/corporate-standard>

³ <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

⁴ <https://ghgprotocol.org/standards/scope-3-standard>